ARTIVA BIOTHERAPEUTICS INC

Artiva insider trading: CMO Subhashis Banerjee’s 10b5‑1 buys and sells show steady confidence in the biotech’s growth, hinting at future upside for investors.

Insider sales at Artiva Biotherapeutics reveal routine tax‑cover actions tied to RSU vesting, not a sign of trouble, and the company’s strong NK‑cell pipeline and market traction remain intact.

Artiva Biotherapeutics insider buys, RSU and ESO awards reveal confidence in NK‑cell therapy AB‑NK‑01, promising breakthrough cancer treatment.